Jean Francois Formela
CIK 1030575 · last filed 2026-09-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NTLA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
890 WINTER STREET
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KRRO | Director | 132,650 | $15.11 | $2.00M | -$5.16M | 11 | 2026-09-15 |
| ImageneBio, Inc. (IKNA) Delisted | Director | 241,801 | $17.16 | $4.15M | $1.61M | 6 | 2024-06-10 |
| NTLA | Director | 45,416 | $12.09 | $549.1K | -$155.43M | 20 | 2022-06-16 |
| Translate Bio, Inc. (TBIO) Delisted | Director | 0 | $0.00 | $0 | -$82.92M | 7 | 2021-09-14 |
| SPRO | Director | 1,979,557 | $1.07 | $2.13M | $6.00M | 6 | 2021-08-18 |
| Zyla Life Sciences (EGLT) Delisted | Director | 1,696,852 | — | — | $500.0K | 1 | 2014-02-12 |
| Oruka Therapeutics, Inc. (ABIO) Delisted | Director | 174 | $28.80 | $5.0K | -$1.06M | 5 | 2012-10-24 |
| Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Director | 3,688,294 | $116.30 | $428.95M | $6.33M | 2 | 2012-03-06 |
| ACHILLION PHARMACEUTICALS INC (TPTX) Delisted | Director | — | $76.01 | — | $0 | 1 | 2007-12-18 |
| SGX PHARMACEUTICALS, INC. (SGXP) Delisted | Director | — | — | — | $0 | 2 | 2007-07-18 |
Recent Filings · Page 2 of 7
62 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-10 | ImageneBio, Inc. (IKNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-04-23 | KRRO | Grant (A) | +17,857 | $1000.0K | EDGAR |
| 2023-11-07 | — | Grant (A) | +1,119,292 | $0 | |
| 2023-06-13 | ImageneBio, Inc. (IKNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-16 | NTLA | Grant (A) | +5,197 | $0 | EDGAR |
| 2022-06-13 | ImageneBio, Inc. (IKNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-12-23 | ImageneBio, Inc. (IKNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-12-14 | ImageneBio, Inc. (IKNA) Delisted | Mixed | +98,722 | $1.61M | EDGAR |
| 2021-09-14 | Translate Bio, Inc. (TBIO) Delisted | Sell (S) | −2,055,063 | -$78.09M | EDGAR |
| 2021-08-18 | SPRO | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.